Skip to main content
SpringerLink
Log in

Alectinib

Hepatotoxicity: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Urbanska EM, et al. Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery. Clinical Lung Cancer 22: e528-e532, No. 4, Jul 2021. Available from: URL: http://www.journals.elsevier.com/clinical-lung-cancer/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alectinib. Reactions Weekly 1888, 22 (2022). https://doi.org/10.1007/s40278-022-08364-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-08364-7

Search

Navigation